<H1>Chapter DOI: 10.1007/s00105-015-3614-0<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>25</td></tr><tr><td>Springer references</td><td>0</td></tr><tr><td>Non Springer references</td><td>25</td></tr><tr><td>BibStructured Count</td><td width="10%">24</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>22</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>2</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>2</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>2</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>2</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Gerami P, Jewel SS, Morrison LE et al (2009) Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 33:1146&#8211;1156</td><td><a href=http://dx.doi.org/10.1097/PAS.0b013e3181a1ef36>10.1097/PAS.0b013e3181a1ef36</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Gerami P, Li G, Pouryazdanparast P et al (2012) A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol 36:808&#8211;817</td><td><a href=http://dx.doi.org/10.1097/PAS.0b013e31824b1efd>10.1097/PAS.0b013e31824b1efd</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Tsao H, Chin L, Garraway LA, Fisher DE (2012) Melanoma: from mutations to medicine. Genes Dev 26:1131&#8211;1155</td><td><a href=http://dx.doi.org/10.1101/gad.191999.112>10.1101/gad.191999.112</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Goldstein AM, Chan M, Harland M et al (2007) Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 44:99&#8211;106</td><td><a href=http://dx.doi.org/10.1136/jmg.2006.043802>10.1136/jmg.2006.043802</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Fargnoli MC, Gandini S, Peris K et al (2010) MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis. Eur J Cancer 46:1413&#8211;1420</td><td><a href=http://dx.doi.org/10.1016/j.ejca.2010.01.027>10.1016/j.ejca.2010.01.027</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Puntervoll HE, Yang XR, Vetti HH et al (2013) Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants J Med Genet 50:264&#8211;270</td><td><a href=http://dx.doi.org/10.1136/jmedgenet-2012-101455>10.1136/jmedgenet-2012-101455</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Yokoyama S, Woods SL, Boyle GM et al (2011) A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 480:99&#8211;103</td><td><a href=http://dx.doi.org/10.1038/nature10630>10.1038/nature10630</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Wiesner T, Obenauf AC, Murali R et al (2011) Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 43:1018&#8211;1021</td><td><a href=http://dx.doi.org/10.1038/ng.910>10.1038/ng.910</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Aoude LG, Wadt KA, Pritchard AL, Hayward NK (2014) Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res 28:148&#8211;160. doi:10.1111/pcmr.12333</td><td><a href=http://dx.doi.org/10.1111/pcmr.12333>10.1111/pcmr.12333</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Horn S, Figl A, Rachakonda PS et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339:359&#8211;361</td><td><a href=http://dx.doi.org/10.1126/science.1230062>10.1126/science.1230062</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, Author_FamilyName_2, ArticleTitle, Author_FamilyName_1, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Robles-Espinoza CD, Harland M, Ramsay AJ et al (2014) POT1 loss-of-function variants predispose to familial melanoma. Nat Genet 46:478&#8211;481</td><td><a href=http://dx.doi.org/10.1038/ng.2947>10.1038/ng.2947</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Aoude LG, Pritchard AL, Robles-Espinoza CD et al (2015) Nonsense Mutations in the Shelterin Complex Genes ACD and TERF2IP in Familial Melanoma. J Natl Cancer Inst 107:1&#8211;7</td><td><a href=http://dx.doi.org/10.1093/jnci/dju408>10.1093/jnci/dju408</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Van Raamsdonk CD, Griewank KG, Crosby MB et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363:2191&#8211;2199</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1000584>10.1056/NEJMoa1000584</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Wu H, Goel V, Haluska FG (2003) PTEN signaling pathways in melanoma. Oncogene 22:3113&#8211;3122</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1206451>10.1038/sj.onc.1206451</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Paraiso KH, Xiang Y, Rebecca VW et al (2011) PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71:2750&#8211;2760</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-10-2954>10.1158/0008-5472.CAN-10-2954</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Papp T, Pemsel H, Zimmermann R et al (1999) Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 36:610&#8211;614</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibArticle</td><td>van Engen-van Grunsven AC, K&#252;sters-Vandevelde HV, De Hullu J et al (2014) NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract&#8211;a study of 24 cases from the Netherlands. Gynecol Oncol 134:10&#8211;14</td><td><a href=http://dx.doi.org/10.1016/j.ygyno.2014.04.056>10.1016/j.ygyno.2014.04.056</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Massi</span> <span style='background:#DDDDDD'>D</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Simi</span> <span style='background:#DDDDDD'>L</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Sensi</span> <span style='background:#DDDDDD'>E</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#FFD9B3'>Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma</span> . Mod Pathol. doi:10.1038/modpathol.2014.137. [Epub ahead of print]</td><td><a href=http://dx.doi.org/10.1038/modpathol.2014.137>10.1038/modpathol.2014.137</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Lee JH, Choi JW, Kim YS (2011) Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol 164:776&#8211;784</td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.2010.10185.x>10.1111/j.1365-2133.2010.10185.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Devitt B, Liu W, Salemi R et al (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24:666&#8211;672</td><td><a href=http://dx.doi.org/10.1111/j.1755-148X.2011.00873.x>10.1111/j.1755-148X.2011.00873.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Nazarian R, Shi H, Wang Q et al (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973&#8211;977</td><td><a href=http://dx.doi.org/10.1038/nature09626>10.1038/nature09626</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Joseph RW, Sullivan RJ, Harrell R et al (2012) Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35:66&#8211;72</td><td><a href=http://dx.doi.org/10.1097/CJI.0b013e3182372636>10.1097/CJI.0b013e3182372636</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Ascierto PA, Schadendorf D, Berking C et al (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14:249&#8211;256</td><td><a href=http://dx.doi.org/10.1016/S1470-2045(13)70024-X>10.1016/S1470-2045(13)70024-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Lyle M, Long GV (2013) Diagnosis and treatment of KIT-mutant metastatic melanoma. J Clin Oncol 31:3176&#8211;3181</td><td><a href=http://dx.doi.org/10.1200/JCO.2013.50.4662>10.1200/JCO.2013.50.4662</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Meckbach D, Bauer J, Pflugfelder A et al (2014) Survival according to BRAF-V600 tumor mutations&#8211;an analysis of 437 patients with primary melanoma. PloS One 9:e86194</td><td><a href=http://dx.doi.org/10.1371/journal.pone.0086194>10.1371/journal.pone.0086194</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>